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Abstract
Nef is the viral gene product employed by the majority of primate lentiviruses to overcome restriction by tetherin (BST-2 or
CD317), an interferon-inducible transmembrane protein that inhibits the detachment of enveloped viruses from infected
cells. Although the mechanisms of tetherin antagonism by HIV-1 Vpu and HIV-2 Env have been investigated in detail,
comparatively little is known about tetherin antagonism by SIV Nef. Here we demonstrate a direct physical interaction
between SIV Nef and rhesus macaque tetherin, define the residues in Nef required for tetherin antagonism, and show that
the anti-tetherin activity of Nef is dependent on clathrin-mediated endocytosis. SIV Nef co-immunoprecipitated with rhesus
macaque tetherin and the Nef core domain bound directly to a peptide corresponding to the cytoplasmic domain of rhesus
tetherin by surface plasmon resonance. An analysis of alanine-scanning substitutions identified residues throughout the N-
terminal, globular core and flexible loop regions of Nef that were required for tetherin antagonism. Although there was
significant overlap with sequences required for CD4 downregulation, tetherin antagonism was genetically separable from
this activity, as well as from other Nef functions, including MHC class I-downregulation and infectivity enhancement.
Consistent with a role for clathrin and dynamin 2 in the endocytosis of tetherin, dominant-negative mutants of AP180 and
dynamin 2 impaired the ability of Nef to downmodulate tetherin and to counteract restriction. Taken together, these results
reveal that the mechanism of tetherin antagonism by Nef depends on a physical interaction between Nef and tetherin,
requires sequences throughout Nef, but is genetically separable from other Nef functions, and leads to the removal of
tetherin from sites of virus release at the plasma membrane by clathrin-mediated endocytosis.
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Introduction
Mammalian cells express a number of proteins that inhibit
specific steps of virus replication. One such factor, tetherin (BST-2
or CD317), impairs the release of enveloped viruses from infected
cells [1,2,3,4,5]. Tetherin is a type II integral membrane protein
with a topology that allows both ends of the molecule to be
anchored in lipid membranes [6]. It has an N-terminal cytoplas-
mic domain followed by a single-pass transmembrane domain, an
extracellular coiled-coil domain and a C-terminal glycosyl-
phosphatidylinositol (GPI) anchor [6]. Under conditions of
interferon-induction, tetherin is upregulated and becomes incor-
porated into virus particles as they attempt to bud from infected
cells [7,8,9]. Captured virions are then internalized and routed to
lysosomal compartments for degradation by a mechanism that
involves interactions between the cytoplasmic domain of tetherin
and the endocytosis machinery of the cell [7,10].
Tetherin has played an important role in shaping the course of
lentiviral evolution in primates, having selected for at least three
different viral gene products to overcome this restriction factor
(reviewed in [11,12]). Whereas HIV-1 Vpu and HIV-2 Env
antagonize human tetherin [4,5,13], the majority of SIVs use Nef
to counteract the tetherin proteins of their non-human primate
hosts [14,15,16]. Indeed, HIV-1 Vpu and HIV-2 Env appear to
have acquired the ability to antagonize tetherin due to the absence
of sequences in the cytoplasmic domain of human tetherin that
confer susceptibility to Nef [11,12].
Alternative models have been proposed for the mechanism of
tetherin antagonism by HIV-1 Vpu. Vpu physically associates with
tetherin via membrane-spanning domain interactions
[17,18,19,20], recruits ßTrCP-2, a component of the Skp1-
Cullin1-F-box ubiquitin ligase complex, promoting the ubiquitina-
tion of non-lysine residues in the cytoplasmic domain of tetherin
[21,22], and uses the ESCRT-mediated trafficking of tetherin [23]
for degradation in lysosomes [17,19,24,25,26]. There is also
evidence that Vpu may antagonize tetherin in the absence of
degradation by sequestering the protein in a perinuclear
compartment, either by retaining newly synthesized tetherin, or
by blocking the recycling of tetherin to the plasma membrane
[24,27,28,29]. Vpu-mediated downmodulation of tetherin and
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enhancement of virus release were also recently shown to be
dependent in part on clathrin-mediated endocytosis [30].
The mechanism of tetherin antagonism by HIV-2 Env depends
on a physical interaction between Env and tetherin, and a
conserved tyrosine-based endocytosis motif in the cytoplasmic tail
of gp41 [13,31,32]. The sequences required for Env interactions
with tetherin are poorly defined, but appear to reside in the
extracellular domains of both proteins, as indicated by analyses of
recombinant forms of Env and tetherin [13,33], and the
identification of substitutions in the ectodomains of each protein
that disrupt tetherin antagonism [32,33,34,35]. HIV-2 Env does
not promote the degradation of tetherin, but leads to the
internalization and sequestration of tetherin by a clathrin-
dependent mechanism, consistent with the trapping of tetherin
in recycling endosomes [13,30,31].
Comparatively little is known about the mechanism of tetherin
antagonism by Nef. The Nef proteins of phylogenetically diverse
SIVs, including SIVsmm/mac, SIVagm and SIVcpz, antagonize the
tetherin proteins of their non-human primate hosts, but not
human tetherin [14,15,16]. This specificity maps to a five amino
acid sequence that is present in the cytoplasmic tails of non-human
primate tetherin proteins (G/D14DIWK18 in rhesus macaques,
sooty mangabeys and chimpanzees), but absent from the
corresponding region of human tetherin [15,16]. We previously
reported that SIV Nef downregulates rhesus tetherin from the
surface of transfected and infected cells [15,36]. Zhang et al.
further demonstrated that this activity is AP-2-dependent [37].
Here we demonstrate a direct physical interaction between SIV
Nef and rhesus tetherin, define residues throughout Nef required
for tetherin antagonism, and demonstrate that the anti-tetherin
activity of Nef is dependent, at least in part, on clathrin-mediated
endocytosis.
Results
SIV Nef binds selectively to the cytoplasmic domain of
rhesus tetherin
SIV Nef was tested for a physical interaction with tetherin by
co-immunoprecipitation. Tetherin was immunoprecipitated from
lysates of 293T cells co-transfected with constructs expressing Nef
and either human or rhesus macaque tetherin. Immunoprecipi-
tated proteins were separated by SDS-PAGE, and western blots
were probed with monoclonal antibodies to Nef and to tetherin. In
accordance with the selective activity of Nef in opposing restriction
by tetherin [15,16], SIV Nef strongly co-immunoprecipitated with
rhesus tetherin, but not with human tetherin (Figure 1A).
To determine if this interaction is direct, SIV Nef was tested for
binding to peptides corresponding to the N-terminal cytoplasmic
domains of rhesus and human tetherin by surface plasmon
resonance (SPR). Tetherin peptides were biotinylated at conserved
cysteine residues (C25 in rBST-2 and C20 in hBST-2) and coupled
to the surface of neutravidin-coated CM5-BIAcore chips to mimic
the native orientation of the N-terminus of tetherin on the inner
leaflet of the plasma membrane. Recombinant SIVmac239 Nef
proteins containing residues 4–263 (Nef4–263) and 96–237 (Nef96–
237) were flowed over the immobilized peptides to assess binding.
SIV Nef96–237 bound to the N-terminal peptide of rhesus tetherin
(Figure 1B), but not to the corresponding peptide of human
tetherin (Figure 1C). The dissociation constant and the maximum
response for SIV Nef96–237 binding to rhesus tetherin were
determined by equilibrium analysis (Kd.app 401+/2114 mM)
(Figure 1D). The nearly full-length Nef protein, Nef4–263, also
bound to rhesus tetherin (data not shown). However, the Kd of this
interaction could not be determined due to artifacts at protein
concentrations greater than 300 mM that may reflect Nef
dimerization. These results reveal a direct physical interaction
between SIV Nef and the cytoplasmic domain of rhesus macaque
tetherin.
Identification of SIV Nef residues required for tetherin
antagonism
To identify sequences in SIV Nef that contribute to tetherin
antagonism, 103 pair-wise alanine-scanning substitutions were
introduced throughout the N-terminal, globular core and the
flexible loop regions of SIVmac239 Nef (residues 3–210), and
these mutants were tested for their ability to counteract rhesus
tetherin in virus release assays (Figure 2). Mutations in the C-
terminal domain (residues 211–263) were not tested, since
these sequences can be deleted without affecting the anti-
tetherin activity of Nef (data not shown). Virus release for 43 of
the Nef mutants was reduced to a similar or greater extent than
a myristoylation site mutant (G2A), which was previously
shown to impair tetherin antagonism [15]. These results were
corroborated by western blot analyses comparing p55 Gag
expression in cell lysates to the accumulation of p27 capsid
(CA) in the cell culture supernatant (Figure S1). This approach
identified 9 substitutions in the N-terminal domain (Figure 2B),
27 substitutions in the globular core domain (Figure 2C), and 7
substitutions in the flexible loop region of Nef (Figure 2D) that
disrupt tetherin antagonism.
Identification of residues that contribute to the
interaction between Nef and tetherin
To define residues in SIV Nef that contribute to interactions
with tetherin, Nef mutants lacking anti-tetherin activity were tested
for binding to rhesus tetherin by co-immunoprecipitation
(Figure 3A). The ratios of the band intensities for Nef and tetherin
in immunoprecipitates were calculated to quantify differences in
binding to tetherin (Table 1). Substitutions at positions 2, 5–6, 66–
67, 68–69 and 70–71 in the N-terminal domain, positions 116–
117 and 174–175 in the globular core domain, and positions 181–
182, 193–194, 195–196 and 199–200 in the flexible loop region
diminished the co-immunoprecipitation of Nef with tetherin
(Figure 3A, 3B and Table 1). Some of the substitutions in the
globular core, particularly at positions 178–179 and 180–181,
resulted in reduced levels of Nef protein in cell lysates (Figure 3A
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Tetherin (BST-2, CD317 or HM1.24) is an interferon-
inducible cellular restriction factor that prevents the
release of enveloped viruses from infected cells. Human
and simian immunodeficiency viruses have evolved to use
different viral proteins to overcome the anti-viral effects of
tetherin. Whereas HIV-1 Vpu and HIV-2 Env counteract
human tetherin, most SIVs use the accessory protein Nef to
counteract tetherin in their non-human primate hosts.
Here we show that the mechanism of tetherin antagonism
by SIV Nef involves a direct physical interaction between
the core domain of Nef and the cytoplasmic domain of
tetherin, which results in the removal of tetherin from sites
of virus assembly and release on the cell surface by a
mechanism that depends on clathrin and dynamin 2. The
Nef-mediated internalization of tetherin leads to the
accumulation of tetherin within lysosomal compartments,
suggesting that, similar to CD42 and MHC I-downregula-
tion, Nef promotes the lysosomal degradation of tetherin.
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and Table 1). Hence, the loss of tetherin binding in these instances
may reflect decreased Nef protein stability or expression rather
than a disruption of tetherin contact residues. However, many of
the core domain mutations that decreased steady-state levels of
Nef did not result in a corresponding decrease in binding to
tetherin, and a few paradoxically appear to have increased the
stability of this interaction (Figure 3A and Table 1). Since many of
these mutations did not completely abrogate binding to tetherin,
combinations of alanine substitutions were also tested. The co-
immunoprecipitation of Nef with tetherin was reduced to nearly
undetectable levels by combining substitutions in the N-terminal
domain, either alone (residues 66–71), or together with the
substitutions in the globular core and flexible loop (x6: residues
66–71, 116–117, 174–175 and 181–182) (Figure 3B).
To determine if residues in the flexible loop of SIV Nef are
needed for direct binding to rhesus tetherin, purified Nef proteins
with deletions in the flexible loop were tested for binding to the
cytoplasmic domain of rhesus tetherin by SPR. Recombinant
SIVmac239 Nef96–237 lacking residues 181–200, 181–195, 197–205
and 181–205 were flowed over BIAcore chips coated with a 26
amino acid peptide corresponding to the cytoplasmic domain of
rhesus tetherin, as described for Figure 1B. All of the deletion
mutants bound to the peptide within a similar range of apparent
Kd values (Figure 3C; representative raw SPR data is shown in
Figure S2A and S2B). The somewhat lower Kd.app estimates for
three of the deletion mutants (D181–200, D181–195 and D181–
205) may be due to technical limitations with testing these mutants
at high concentrations as a result of protein aggregation, rather
Figure 1. SIV Nef physically interacts with the cytoplasmic domain of rhesus tetherin. (A) 293T cells were co-transfected with constructs
expressing SIV Nef and either rhesus tetherin (rBST-2), human tetherin (hBST-2) or empty vector. Cell lysates were immunoprecipitated with a
monoclonal antibody to tetherin, proteins were separated by SDS-PAGE and transferred to PVDF membranes. Western blots were developed with a
monoclonal antibody to SIV Nef. Western blots were also performed for whole cell lysates to determine the input levels of these proteins. (B & C)
Surface plasmon resonance (SPR) analyses were performed to test for direct binding between Nef and rhesus tetherin or human tetherin. Peptides
corresponding to the cytoplasmic domain of rBST-2 and hBST-2 were biotinylated at conserved cysteines and captured on neutravidin-coated CM5
sensor chips. The binding of Nef to tetherin was assessed by flowing purified recombinant SIVmac239 Nef4–263 and Nef96–237 proteins over the
peptide-coated biosensor chips. (D) The dissociation constant and maximum response rate for this interaction were determined by equilibrium
analysis (see materials and methods for details).
doi:10.1371/journal.ppat.1003487.g001
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Figure 2. Identification of residues in SIV Nef necessary for tetherin antagonism. (A) Predicted amino acid sequence of SIVmac239 Nef. The
highlighted sequences correspond to the N-terminal domain (green), the globular core (blue), and the flexible loop region (orange). Substitutions in
residues that impaired tetherin antagonism are underlined and in bold. (B, C and D) 293T cells were co-transfected with SIV Dnef proviral DNA
together with constructs expressing rhesus tetherin and either wild-type or mutant Nef proteins. The percentage of virus release was determined by
Tetherin Antagonism by SIV Nef
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measuring the accumulation of SIV p27 in the culture supernatant in the presence of tetherin relative to transfections with empty vector. Controls
include virus release in the absence of Nef (pCGCG; white), wild-type Nef (black) and Nef with a glycine-to-alanine substitution in the myristoylation
site (G2A; red). Substitutions in the N-terminal domain are indicated by green bars (B), substitutions in the globular core domain are indicated by blue
bars (C), and substitutions in the flexible loop region are indicated by orange bars (D). Error bars represent the standard deviation of duplicate
transfections and the dotted line indicates 3 standard deviations over the activity of the G2A mutant.
doi:10.1371/journal.ppat.1003487.g002
Figure 3. Identification of residues in SIV Nef that contribute to interactions with tetherin. (A) Co-immunoprecipitation assays with the
Nef mutants that impair anti-tetherin activity were performed to identify residues that diminish binding to tetherin. 293T cells were co-transfected
with constructs expressing rhesus tetherin, and either wild-type or mutant Nef proteins. Cell lysates were immunoprecipitated using a monoclonal
antibody to tetherin, and blots were probed with monoclonal antibodies to SIV Nef and tetherin. (B) Combinations of alanine substitutions in Nef that
were shown to impair binding to rhesus tetherin in panel A were tested in additional co-immunoprecipitation assays as described above. (C)
Estimated Kd.app values were determined for the binding of SIVmac239 Nef96–237 with the indicated deletions in the flexible loop region to the
cytoplasmic domain of rhesus tetherin by SPR. Bands corresponding to the antibody heavy and light chain are indicated (HC and LC). Asterisks
indicate the absence of detectable Nef protein.
doi:10.1371/journal.ppat.1003487.g003
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Table 1. Summary of the properties of the SIV Nef mutants lacking anti-tetherin activity.
% BST2 antagonisma BST2 bindingb Nef levelsc % CD4 expressiond % MHC I expressione Relative infectivityf
Nef 100 1 1 37.13 41.40 1
G2A 32.04 0.16 1.02 79.43 93.57 0.81
**
5–6 21.43 0.18 1.18 60.76 91.70 0.79**
60–61 24.77 0.70 1.22 71.95 38.73** 0.96**
64–65 25.09 0.54 1.18 71.54 32.44** 0.39
66–67 16.94 0.18 1.07 76.49 31.18** 0.43
68–69 18.36 0.14 1.05 73.93 30.12** 0.27
70–71 28.41 0.28 1.37 75.57 28.71** 0.69**
74–75 10.27 0.71 1.44 83.75 81.31 1.01**
82–83 21.00 1.38 0.44 72.13 22.40** 0.51
86–87 27.68 0.47 0.52 42.33** 29.32** 0.79**
88–89 26.91 0.93 1.12 76.28 38.57** 0.76**
106–107 53.63 0.82 1.23 39.61** 47.24** 0.87**
108–109 38.43 1.87 0.82 79.18 89.30 0.76**
110–111 34.26 1.29 0.75 65.06 105.52 0.91**
112–113 26.48 0.35 0.72 62.81 95.97 0.59
116–117 31.34 0.16 0.56 102.68 118.09 0.80**
128–129 35.45 1.11 0.70 51.97* 86.41 1.33**
130–131 46.05 2.40 0.42 58.22 91.15 1.29**
132–133 40.73 0.79 0.53 64.43 49.67** 0.80**
134–135 25.34 2.58 1.1 113.12 117.88 0.77**
138–139 50.33 0.84 0.97 51.51* 60.97 0.66**
140–141 45.83 1.38 0.71 60.06 56.69** 0.72**
142–143 23.44 5.10 0.60 95.17 111.06 0.79**
146–147 32.24 1.56 0.52 105.17 104.02 0.50
152–153 21.50 1.68 0.62 97.31 103.37 1.1**
156–157 23.80 1.46 0.86 110.99 100.27 0.85**
158–159 8.83 0.76 0.60 78.49 87.17 0.70**
160–161 18.60 1.64 0.58 55.78* 93.18 1.05**
164–165 14.13 1.34 0.63 82.35 97.46 0.74**
166–167 13.40 1.40 0.33 83.53 113.26 0.88**
168–169 10.24 2.10 0.33 86.10 88.91 0.54
170–171 16.29 2.61 0.35 54.84* 92.21 0.67**
172–173 12.08 1.34 0.40 81.75 98.37 1.06**
174–175 14.82 0.52 0.2 87.02 93.68 0.72**
176–177 15.34 3.17 0.27 63.49 103.43 0.74**
178–179 12.5 0.17 0.05 101.49 95.05 0.39
180–181 10.97 0.02 0.04 102.40 92.77 0.43
181–182 27.99 0.23 1.11 29.77** 34.02** 0.86**
193–194 14.86 0.22 1.35 49.56** 32.95** 0.80**
195–196 17.45 0.31 1.13 68.21 36.54** 0.42
199–200 20.06 0.43 1.22 38.48** 30.86** 0.74**
203–204 13.03 0.74 1.34 68.55 26.83** 0.93**
205–206 11.01 0.94 1.40 75.20 38.95** 0.84**
209–210 13.55 1.40 1.07 52.63* 55.94* 0.66**
aThe percentage of BST-2 antagonism was calculated as the amount of SIV p27 released into the culture supernatant of 293T cells transfected with constructs
expressing each of the Nef mutants in the presence of rhesus tetherin relative to the amounts of SIV p27 released in the absence of tetherin.
bBinding to BST-2 was calculated as the relative band intensity of Nef to the band intensity of tetherin in immunoprecipitated samples.
cSteady-state levels of Nef protein in cell lysates were estimated by calculating the relative band intensity of each of the Nef mutant proteins compared to wild-type Nef.
dCD4 levels were calculated as the percentage of CD4 staining (MFI) on cells transfected with each of the indicated Nef-expression constructs relative to CD4 staining
(MFI) on cells transfected with an empty vector.
eMHC class I levels were calculated as the percentage of MHC I staining (MFI) on cells transfected with each of the indicated Nef-expression constructs relative to MHC I
Tetherin Antagonism by SIV Nef
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than an actual increase in binding affinity. Some of these mutants
also showed lower apparent Kd values for binding to a TCRf
chain peptide (Figure S2C–S2E), an interaction that reflects direct
binding of the SIV Nef core domain as corroborated by three-
dimensional structural data [38]. Hence, these results demonstrate
that the flexible loop of Nef is not required for direct binding to
rhesus tetherin, implying that surfaces of the core domain are
sufficient for the low affinity interaction with the N-terminus of
rhesus tetherin observed by SPR.
Cytoplasmic domain variants of tetherin were also tested for
binding to Nef by co-immunoprecipitation and SPR. Deletion of
the first 10 amino acids of rhesus tetherin (rD10) significantly
reduced, but did not eliminate, binding to Nef in both assays
(Figures 4A, 4B and S3B), indicating that although these residues
are not essential for binding to Nef, they contribute to the stability
of the interaction. Consistent with previous studies mapping the
anti-tetherin activity of Nef to a five amino acid sequence (G/
D14DIWK18) that is missing from human tetherin [15,16], alanine
substitutions at positions 14–18 of rhesus tetherin (rA14-A18)
diminished Nef binding, whereas the introduction of these residues
into human tetherin partially restored binding (Figures 4A, 4B,
S3C and S3D). Thus, although the specificity of tetherin
antagonism by Nef is dependent on residues 14–18, and these
sequences contribute to a physical interaction with Nef, they are
not the sole determinant of Nef binding.
These tetherin variants were also tested in virus release assays to
determine how Nef binding relates to susceptibility to antagonism.
In accordance with partial binding of Nef to rD10 and hDDIWK,
restriction of virus release by each of these mutants was partially
counteracted by Nef (Figure 4C). However, despite a physical
interaction between rA14-A18 and Nef that was detectable by co-
immunoprecipitation and SPR assays, this mutant was resistant to
antagonism and restricted virus release to an extent comparable to
human tetherin (Figure 4C). Therefore, although a physical
interaction may be necessary for tetherin antagonism by Nef, it is
not sufficient. This raises the possibility that the anti-tetherin
activity of Nef may require the recruitment of one or more
additional cellular factors that participate in interactions with the
G/D14DIWK18 sequence.
Tetherin antagonism is separable from CD4-
dowregulation, MHC class I-downregulation and
infectivity enhancement
To determine if substitutions that impair tetherin antagonism
also disrupt other activities of Nef, the Nef mutants were tested for
CD4-downregulation, MHC I-downregulation and infectivity
enhancement; three functional activities of Nef that require
distinct protein sequences and cellular pathways [39,40]. CD42
and MHC class I-downregulation assays were performed by
electroporating Jurkat cells with bicistronic constructs that express
wild-type Nef, or a mutant Nef protein, together with green
fluorescent protein (GFP), and comparing the mean fluorescence
intensity (MFI) of CD4 and MHC class I staining on the surface of
cells expressing Nef to cells transfected with an empty vector
(pCGCG) (Figures S4 and S5). Infectivity enhancement was
measured by infecting GHOST X4/R5 cells, which express GFP
in response to HIV-1 or SIV infection, with SIVmac239 Dnef trans-
complemented with wild-type Nef or each of the Nef mutants, and
measuring the percentage of infected GFP+ cells by flow cytometry
(Figure S6).
Of the 43 Nef mutants with impaired anti-tetherin activity, only
5 retained the ability to downregulate CD4 within 3 standard
deviations of wild-type Nef (Figure 5A, black dotted line). In
contrast, 16 of the mutants retained the ability to downregulate
MHC I within 3 standard deviations of wild-type Nef (Figure 5B,
black dotted line). Whereas substitutions in the N-terminal domain
and flexible loop region, with the exception of substitutions at
positions 5–6 and 74–75, had little or no effect on MHC I-
downregulation, many of the substitutions in the globular core
impaired this activity (Figure 4B and S5). In most cases, the loss of
MHC I-downregulation corresponded with a partial decrease in
Nef protein levels (Table 1), suggesting that the effects of these
mutations were not necessarily specific to this function of Nef.
Nevertheless, five Nef mutants with impaired anti-tetherin activity,
and no significant effects on protein stability, retained the ability to
downregulate both CD4 and MHC I molecules. These included
Nef mutants with substitutions at positions 106–107, 181–182,
193–194, 199–200 and 209–210 (Table 1). Therefore, tetherin
antagonism is separable from CD42 and MHC class I-downreg-
ulation.
The infectivity of SIV Dnef trans-complemented with each of the
Nef mutants relative to SIV Dnef trans-complemented with wild-
type Nef was also determined to assess the effects of the
substitutions on Nef-mediated infectivity enhancement. To control
for assay-to-assay variation in the susceptibility of the GHOST
X4/R5 cells to infection, the percentage of infected cells obtained
for each of the Nef mutants was normalized to the percentage of
infected cells obtained for wild-type Nef. Nef mutants were
considered to retain the ability to enhance virus infectivity if the
relative infectivity was at least 5 standard deviations above the
infectivity of SIV Dnef trans-complemented with an empty vector
(pCGCG) (Figure 5C). This analysis identified 12 Nef mutants that
were impaired for infectivity enhancement (Figure S6A–S6C). In
accordance with previous observations, the G2A substitution in
SIV Nef did not have a significant effect on virus infectivity [41].
Consistent with a study of this function of HIV-1 Nef [40], all of
these mutants also lost the ability to bind to dynamin 2 (Dyn2)
(Figure S6D). Of these 12 Nef mutants, 10 also exhibited impaired
anti-tetherin activity, suggesting that tetherin antagonism and
infectivity enhancement may be linked, perhaps by a common
dependence on a physical interaction with Dyn2. However, two of
the substitutions in the core domain at positions 94–95 and 98–99
that disrupted infectivity enhancement did not significantly affect
anti-tetherin activity (Figure 2C and S6B). Moreover, three of the
substitutions that disrupted binding to Dyn2 (82–83, 146–147 and
168–169) did not impair binding to rhesus tetherin (Table 2).
Thus, Nef appears to use distinct surfaces to bind Dyn2 and
staining (MFI) on cells transfected an with empty vector.
fGHOST X4/R5 cells were infected with SIV Dnef trans-complemented with the indicated wild-type or mutant Nef proteins, and the relative infectivity was calculated as
the frequency of infected cells obtained for each of the mutants relative to wild-type Nef at 48-hours post-inoculation.
Nef mutants that retain wild-type levels of CD4-downregulation, MHC class I-downregulation or infectivity enhancement are indicated in bold and italics. For CD42 and
MHC class I-downregulation, one asterisk indicates activity within 5 standard deviations of wild-type Nef and two asterisks indicate activity within 3 standard deviations
of wild-type Nef. For infectivity enhancement, two asterisks indicate infectivity 5 standard deviations or more over SIV Dnef trans-complemented with empty vector.
doi:10.1371/journal.ppat.1003487.t001
Table 1. Cont.
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tetherin. In addition, since all but 10 of the 43 Nef mutants lacking
anti-tetherin activity retained the ability to enhance infectivity,
including the 5 mutants that retained both CD42 and MHC class
I-downregulation, infectivity enhancement is independent of
tetherin antagonism (Figure 5C and Table 1).
Mutations in the flexible loop of SIV Nef impair tetherin
downregulation and AP-2 binding
AP-2 binds to a pair of conserved motifs in the flexible loop of Nef
that are necessary for tetherin antagonism; a di-leucine motif and a di-
acidic motif, corresponding to residues E191XXXLM195 and D204D205
of SIVmac239 Nef, respectively (Figure 6A) [37,42,43]. Consistent with
previous observations [37], substitutions of residues within either of
these motifs (positions 193–194, 195–196, 203–204, 205–206)
impaired tetherin downregulation by Nef (Figure 6B and 6C). In
addition, substitutions at positions 181–182, 199–200 and 209–210,
not previously identified as AP-2 binding sites or known to be involved
in the anti-tetherin activity of Nef, also impaired tetherin downregu-
lation (Figure 6B and 6D). These results confirm the role of the di-
leucine and di-acidic motifs and identify additional sequences in the
flexible loop of SIV Nef required for tetherin downmodulation.
Since AP-2 binds to both Nef and tetherin [42,43,44], the
flexible loop mutants were also tested for their ability to interact
with the a-adaptin (a2) and m2 subunits of AP-2 by co-
immunoprecipitation. Endogenous a2 and m2 were immunopre-
cipitated in parallel from lysates of parental 293T cells (Figure 6E),
or 293T cells that constitutively express HA-tagged rhesus tetherin
(Figure 6F), following transfection with Nef expression constructs.
Immunoprecipitates were separated by electrophoresis and west-
ern blots were probed with antibodies to Nef, a2, m2 and tetherin.
Wild-type Nef co-immunoprecipitated with a2 and m2, both in the
absence and in the presence of tetherin (Figures 6E and 6F). As
expected, substitutions in the di-leucine and di-acidic motifs of Nef
(193–194, 195–196, 203–204, 205–206) greatly diminished
binding to both subunits (Figures 6E and 6F). Substitutions at
positions flanking these motifs (181–182 and 209–210) also
disrupted binding to a2 and to m2 (Figures 6E and 6F). Whereas
in the absence of tetherin, substitutions at positions 181–182, 203–
204, 205–206 and 209–210 eliminated Nef binding to m2, and
substitutions at positions 193–194, 195–196, and 199–200 reduced
Nef binding to m2, (Figure 6E), the binding of these Nef mutants to
m2 was partially restored in the presence of tetherin (Figure 6F).
These results suggest that the loss of anti-tetherin activity for each
Figure 4. Identification of residues in rhesus tetherin that contribute to interactions with Nef. Mutations in the cytoplasmic domain of
rhesus and human tetherin were tested for their effects on binding to Nef by co-immunoprecipitation and SPR assays. (A) Co-immunoprecipitation of
Nef in the presence of rhesus, human tetherin and the following tetherin mutants; a rhesus tetherin mutant lacking the first 10 residues of the protein
(rD10), a rhesus tetherin mutant containing five alanine substitutions at positions 14–18 (rA14-A18) and a human tetherin mutant containing residues
D14DIWK18 from rhesus tetherin (hDDIWK). The ratios of the band intensities of Nef versus tetherin in the immunoprecipitates are shown beneath
each lane. (B) SPR assays were performed as described in Figure 1 to assess binding for Nef96–237 and peptides corresponding to the tetherin mutants
tested in panel A. (C) Virus release assays were performed to test the susceptibility of each of these tetherin mutants to Nef antagonism. 293T cells
were co-transfected with SIVmac239 Dnef proviral DNA and constructs coding for rhesus, human tetherin, each tetherin mutant or an empty vector.
Constructs coding for Nef were provided in trans. Virus release was measured by SIV p27 antigen-capture ELISA and expressed as the percentage of
maximal release in the absence of tetherin.
doi:10.1371/journal.ppat.1003487.g004
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Figure 5. CD4-downregulation, MHC class I-downregulation and infectivity enhancement mediated by SIV Nef mutants with
impaired anti-tetherin activity. The surface expression of CD4 (A) and MHC class I (B) was compared on cells expressing each of the SIV Nef
mutants. Jurkat cells were electroporated with a bicistronic vector (pCGCG) expressing either wild-type Nef or the indicated Nef mutants together
with GFP. Cells were stained with a PerCP-conjugated monoclonal antibody to CD4 and an APC-conjugated monoclonal antibody to HLA class I
molecules. Cells were gated on the GFP+ cell population and the percentage of CD4 and MHC I on the cell surface was determined relative to cells
transfected with empty vector. Error bars indicate the standard deviation of duplicate transfections, and the black and red dotted lines correspond,
respectively, to 3 and 5 standard deviations over the activity of wild-type Nef. (C) The Nef mutants with impaired anti-tetherin activity were also
tested for infectivity enhancement. Viruses were generated by transient transfection of 293T cells with SIVmac239 Dnef proviral DNA and constructs
expressing each of the Nef mutants, wild-type Nef or an empty vector. The infectivity of these viruses was then determined on GHOST X4/R5 cells,
which express GFP upon SIV infection, 48 hours post-inoculation by flow cytometry. The relative infectivity of SIV Dnef trans-complemented with the
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of the flexible loop mutants reflects a deficit in Nef binding to AP-
2, and raises the possibility that AP-2 may form a multimeric
complex with both Nef and tetherin that stabilizes an otherwise
low affinity direct interaction between these two proteins.
Tetherin antagonism by Nef is dependent on dynamin 2
and clathrin
Since the activities of HIV-1 Vpu and HIV-2 Env in
downregulating tetherin and facilitating virus release were recently
shown to be dependent on AP180, a component of the clathrin
assembly complex [30], and dynamin 2 (Dyn2), an ubiquitously
expressed GTPase required for the scission of vesicular mem-
branes [45], we asked whether tetherin antagonism by Nef also
requires AP180 and Dyn2. The effects of dominant-negative
mutants of Dyn2 (Dyn2K44A) and AP180 (AP180C) on the
surface expression of tetherin, and on virus release, were therefore
tested in 293T cells expressing HA-tagged rhesus macaque
tetherin. As a control, we also included the dominant-negative
mutant of dynamin 1 (Dyn1K44A), which is exclusively expressed
in neurons [46]. Changes in tetherin expression on the cell surface
were assessed by flow cytometry after co-transfection with
constructs expressing Dyn2K44A, Dyn2, Dyn1K44A or
AP180C, with or without Nef (Figure 7A). In the absence of
Nef, Dyn1K44A, Dyn2K44A and AP180C all slightly increased
surface levels of tetherin, whereas wild-type Dyn2 decreased
surface levels of tetherin (Figure 7A), which may reflect a role for
dynamin and clathrin in the constitutive endocytosis of tetherin
[44]. In the presence of Nef, the effects of the dominant-negative
mutants were more pronounced. Whereas SIV Nef reduced the
surface expression of rhesus tetherin by 2- to 3-fold, as previously
reported [15], this effect was almost completely reversed by
AP180C and Dyn2K44A (Figure 7A). Although Dyn1K44A also
increased the overall levels of tetherin at the cell surface, as shown
in transfections with the empty vector, Nef was still able to
downregulate tetherin in the presence of Dyn1K44A (Figure 7A).
Likewise, in the presence of wild-type Dyn2, Nef further decreased
the surface levels of tetherin. These results demonstrate that the
downregulation of tetherin by Nef is dependent, at least in part, on
clathrin-mediated endocytosis.
To further confirm that Dyn2 and clathrin are required for
tetherin antagonism by Nef, virus release for wild-type SIV versus
SIV Dnef was compared in the presence and absence of each of the
dominant-negative mutants. 293T cells were co-transfected with
proviral DNA for SIVmac239 or SIVmac239 Dnef, together with a
construct expressing rhesus macaque tetherin and expression
constructs for AP180C, Dyn1K44A, Dyn2K44A or Dyn2, and the
accumulation of virus particles in the cell culture supernatant was
measured by SIV p27 antigen-capture ELISA. Whereas AP180C
and Dyn2K44A completely abrogated the resistance of wild-type
SIV to rhesus tetherin, as indicated by comparable levels of virus
release for SIVmac239 and SIVmac239 Dnef, virus release for wild-
type SIV was not significantly affected by Dyn1K44A or Dyn2
(Figure 7B). Western blot analyses of cell lysates confirmed protein
expression for tetherin, Nef and the dominant-negative mutants
(Figure 7C). None of the dominant-negative mutants inhibited
tetherin expression. On the contrary, increased steady-state levels
were observed in the presence of AP180C, Dyn1K44A and
Dyn2K44A (Figure 7C), consistent with the modest increase in cell
surface expression of tetherin in the absence of Nef (Figure 7A).
A role for Dyn2 in the anti-tetherin activity of Nef was further
investigated by comparing virus replication of wild-type SIV and
nef-deleted SIV with or without Dynasore, a chemical inhibitor of
dynamin. A Herpesvirus saimiri-immortalized rhesus macaque CD4+
T cell line [47], was infected with SIVmac239 and SIVmac239 Dnef,
treated with IFNa to upregulate tetherin, and maintained in
medium with or without Dynasore. While Dynasore had little
effect on the replication of SIV Dnef, which was suppressed relative
to wild-type SIV by the IFNa-induced upregulation of tetherin,
Dynasore significantly reduced wild-type SIV replication
(Figure 7D). Indeed, wild-type SIV replication in the presence of
Dynasore was comparable to SIV Dnef replication, suggesting that
this compound fully negated the resistance provided by Nef to the
antiviral effects of tetherin. However, since Dyn2 is also required
for infectivity enhancement by Nef [40], these results may reflect
an additional effect of Dynasore on viral infectivity.
Nef promotes the internalization of tetherin in SIV-
infected cells
Changes in the subcellular distribution of tetherin in the presence of
Nef were examined in uninfected and SIV-infected cells by confocal
microscopy. 293T cells expressing HA-tagged rhesus tetherin were
infected with VSV-G-pseudotyped SIVmac239Denv and stained for Nef
and tetherin. In uninfected cells, tetherin was observed at the plasma
membrane and within the trans-Golgi network (Figure 8A and Figure
S7), as previously reported [48]. However, in SIV-infected cells, the
Nef mutants was calculated relative to SIV Dnef trans-complemented with wild-type Nef. Virus infectivity in the absence of Nef is indicated by the
white bars, and the activities mediated by wild-type Nef and the G2A myristoylaton site mutant are indicated by black and red bars, respectively. Error
bars indicate the standard deviation of duplicate infections, and the black and red dotted lines correspond, respectively, to 3 and 5 standard
deviations over the infectivity of SIV Dnef without trans-complementation. Substitutions in the N-terminal domain are indicated by green bars,
substitutions in the globular core domain are indicated by blue bars, and substitutions in the flexible loop region are indicated by orange bars.
doi:10.1371/journal.ppat.1003487.g005
Table 2. Comparison of binding to Dyn2 and tetherin for Nef
substitutions with impaired infectivity enhancement.
Infectivity
enhancementa Dyn2 bindingb BST2 bindingc
Nef 1 1.1 1
G2A 0.81 0.17 0.16
64–65 0.39 0.35 0.54
66–67 0.43 0.46 0.18
68–69 0.27 0.50 0.14
82–83 0.51 0.26 1.38
94–95 0.58 0.17 NT
98–99 0.49 0.50 NT
112–113 0.59 0.18 0.35
146–147 0.50 0.35 1.56
168–169 0.54 0.52 2.1
195–196 0.42 0.22 0.31
aInfectivity enhancement was calculated as the relative infectivity of Dnef-
viruses trans-complemented with these Nef mutants to Dnef-viruses trans-
complemented with wild-type Nef.
bBinding to dynamin 2 was calculated as the relative band intensity of Nef to
the band intensity of dynamin 2 in immunoprecipitated samples.
cBinding to tetherin was calculated as the relative band intensity of Nef to the
band intensity of tetherin in immunoprecipitated samples.
doi:10.1371/journal.ppat.1003487.t002
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overwhelming majority of tetherin was observed within intracellular
compartments (Figure 8B). To better define the subcellular distribution
of tetherin, cells were stained for markers of the trans-Golgi network
(TGN46), endosomes (CD63) and lysosomes (LAMP-1). In some cells,
tetherin co-localized with TGN46 (Figure 9A), but did not appear to
co-localize with CD63 (Figure 9B). These results suggest that Nef may
partially retain tetherin within the trans-Golgi network with little or no
sequestration in endosomes. However, in the majority of the SIV-
infected cells, tetherin was found to co-localize with LAMP-1
(Figure 9C), but not in uninfected cells (Figure S7). These observations
were supported by quantifying the extent of tetherin co-localization
with TGN46, CD63 and LAMP-1 by calculating the Pearson’s
Figure 6. Contribution of flexible loop residues to Nef-mediated antagonism of tetherin and binding to AP-2. (A) Predicted amino acid
sequence of the flexible loop region of the SIVmac239 Nef protein. Substitutions at positions that impair anti-tetherin activity are underlined and in
bold. The di-leucine and di-acidic motifs known to interact with AP-2 are indicated in brackets. (B) Tetherin downregulation by each of the flexible
loop mutants was assessed by transfecting 293T cells that constitutively express HA-tagged rhesus tetherin with constructs expressing the indicated
Nef mutants, and comparing the cell surface expression of tetherin to cells transfected with the empty vector (pCGCG). The percentage of tetherin
expressed on the cell surface was calculated by dividing the MFI of tetherin (HA) staining on cells expressing Nef by the MFI of tetherin on cells
transfected with the empty vector. (C and D) Histogram plots showing the surface expression of tetherin for cells expressing Nef mutants with
substitutions in known AP-2 binding sites (C) and at sites flanking these residues (D). (E and F) Nef mutants with substitutions in the flexible loop
were tested for binding to the a2 and m2 subunits of AP-2 by co-immunoprecipitation. Parental 293T cells (E) or 293T cells that constitutively express
HA-tagged rhesus tetherin (F) were transfected with constructs expressing the indicated Nef mutants, and cell lysates were immunoprecipitated with
monoclonal antibodies to the a2 and m2 subunits of AP-2. Western blots of immunoprecipitates and cell lysates were probed with antibodies to a2,
m2, Nef and tetherin. The ratios of the band intensities of Nef to a2 and Nef to m2 in the immunoprecipitated samples are shown beneath each lane.
doi:10.1371/journal.ppat.1003487.g006
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Figure 7. Tetherin antagonism by Nef depends on clathrin and dynamin 2. (A) Dominant-negative mutants of AP180 and Dyn2 were tested
for disruption of Nef-mediated tetherin downregulation. 293T cells expressing HA-tagged rhesus tetherin were transfected with constructs
expressing Nef, or empty vector, and constructs expressing AP180C, Dyn1K44A, Dyn2K44A and Dyn2. Surface expression of tetherin was measured by
HA staining, and the percentage of tetherin expressed on the cell surface was determined by dividing the MFI of tetherin on cells expressing the
dominant-negative mutants by the MFI of tetherin on cells transfected with empty vectors. (B) The dominant-negative mutants of AP180 and Dyn2
were also tested for their effects on Nef-mediated virus release. 293T cells were transfected with SIVmac239 or SIVmac239 Dnef proviral DNA, and
constructs expressing rhesus tetherin, and either AP180C, Dyn1K44A, Dyn2K44A, Dyn2 or empty vector. Virus release was measured by SIV p27
antigen-capture ELISA and expressed as the percentage of maximal release in the absence of tetherin. (C) Protein expression for Nef, tetherin,
AP180C, Dyn1K44A, Dyn2K44A and Dyn2 was verified by western blot analyses using endogenous b-actin as a loading control. (D) Replication of wild-
type SIV (WT SIV) versus SIV Dnef in the presence and absence of Dynasore. 221 T cells were infected with 20 ng p27 of wild-type SIV or SIV Dnef.
Twenty-four hours post-infection, cells were treated with IFNa (100 U). Eight hours later, Dynasore (20 mM) was added to one of the cultures.
Supernatants were collected at the indicated time points and virus replication was determined by SIV p27 antigen-capture ELISA.
doi:10.1371/journal.ppat.1003487.g007
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correlation coefficients for these markers in twenty SIV-infected cells.
Although the distribution of cells exhibiting co-localization of tetherin
with TGN46 was heterogeneous (Figure 9D), it was higher than the
extent of co-localization with CD63 (P = 0.042). In the case of LAMP-
1, the extent of co-localization with tetherin was significantly higher
than for either TGN46 (P = 0.0048) or CD63 (P,0.000001).
Therefore, similar to the effects of Nef on CD4 and MHC class I
trafficking [49], Nef appears to direct tetherin to lysosomes.
Discussion
The primate lentiviruses have evolved to use at least three
different proteins to counteract tetherin; Nef, Vpu and Env
[5,13,15,16,32,36,50]. Although a number of studies have
addressed the mechanisms of tetherin antagonism by HIV-1
Vpu and HIV-2 Env [4,5,13,18,23,27,29,30,31,51], relatively little
is known about the mechanism of tetherin antagonism by Nef–the
viral gene product used by most SIVs to counteract the tetherin
proteins of their respective hosts. In accordance with the species-
dependent activity of Nef in opposing restriction by tetherin
[15,16], we show for the first time that Nef selectively binds to
rhesus macaque tetherin, but not to human tetherin. We identify
residues in the N-terminus, globular core and flexible loop of Nef
that are required for anti-tetherin activity, and demonstrate that,
despite substantial overlap with sequences required for CD4
downregulation, tetherin antagonism is genetically separable from
this activity, as well as from other Nef functions including MHC
class I downregulation and infectivity enhancement. We also show
that dominant-negative mutants of AP180 and Dyn2 impair
tetherin antagonism by Nef, indicating that this activity is
dependent, at least in part, on clathrin-mediated endocytosis.
Figure 8. Distribution of Nef and tetherin in SIV-infected cells. 293T cells expressing HA-tagged rhesus tetherin were infected with VSV-G
pseudotyped SIVmac239 Denv and stained for tetherin (green), Nef (red) and the cell nucleus (blue). Tetherin expression in uninfected cells (A), and the
localization of Nef and tetherin in SIV-infected cells (B). The white scale bar indicates 10 mm.
doi:10.1371/journal.ppat.1003487.g008
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Figure 9. Subcellular distribution of tetherin in SIV-infected cells. 293T cells expressing HA-tagged rhesus macaque tetherin were infected
with VSV-G pseudotyped SIVmac239 Denv and stained for tetherin (green), Nef (blue) and either TGN46 (red) (A), CD63 (red) (B) or LAMP-1 (red) (C).
The white scale bar indicates 10 mm. (D) The extent of co-localization between tetherin and each of the intracellular markers was estimated by
calculation of the Pearson’s correlation coefficients for images of twenty randomly selected SIV-infected cells.
doi:10.1371/journal.ppat.1003487.g009
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Co-immunoprecipitation and surface plasmon resonance assays
revealed a selective physical interaction between SIV Nef and
rhesus tetherin. The specificity of this interaction is determined by
binding of the core domain of Nef to the cytoplasmic domain of
tetherin, since a truncated form of the SIVmac239 Nef protein,
containing the globular core of the protein, was sufficient for
binding to a peptide corresponding to the cytoplasmic domain of
rhesus tetherin. However, the affinity of this interaction was low
(Kd,400 mM), suggesting that additional Nef sequences, and
perhaps one or more cellular co-factors, contribute to the stability
of this interaction in virus-infected cells. In support of this, an
analysis of alanine-scanning substitutions identified sequences in
the N-terminal, globular core and flexible loop domains of Nef
that participate in binding to rhesus tetherin. Although the N-
terminal domain and flexible loop were dispensable for binding by
SPR, these sequences were required to detect an interaction by co-
immunoprecipitation. The contribution of the N-terminus of Nef
to interactions with tetherin may reflect an indirect effect on
membrane association, since the targeting of Nef to cellular
membranes is dependent on the myristyolation of a glycine residue
at position 2, and structural studies suggest that the N-terminus of
Nef is disordered in the absence of phospholipids [52,53,54].
Substitutions at positions 116–117, 174–175 in the globular core
domain, and positions 181–182, 193–194, 195–196 and 199–200
in the flexible loop region also reduced binding to rhesus tetherin.
Since the flexible loop contains a di-leucine and a di-acidic motif
(E190xxxLM and D204D) required for binding to the AP-2 subunits
(a2-s2 and m2, respectively) [42,55,56], and substitutions in these
sites disrupt tetherin antagonism [37], it is conceivable that AP-2
stabilizes the binding of Nef to tetherin. Indeed, Nef was recently
shown to form a trimolecular complex with the m1 subunit of AP-1
to stabilize an otherwise low affinity bimolecular interaction with
the cytoplasmic tail of MHC class I molecules [57,58]. In support
of a possible trimeric complex with AP-2, Nef and rhesus tetherin
both co-immunoprecipitated with the m2 and a2 subunits of AP-2
[24,44]. Taken together, these results suggest a model in which the
specificity of SIV Nef for rhesus tetherin is driven by a direct
physical interaction between the core domain of Nef and the N-
terminus of tetherin, which is stabilized by residues in the N-
terminal domain and flexible loop region, either through direct
contacts or indirect effects on membrane association and/or the
recruitment of additional cellular co-factor(s).
A systematic analysis of alanine-scanning substitutions through-
out the SIVmac239 Nef protein identified a total of 43 mutations
that impaired anti-tetherin activity. Substitutions in the C-terminal
domain were not tested, since deletion of these sequences did not
affect tetherin antagonism. Most of the mutations that disrupted
the anti-tetherin activity of Nef also disrupted CD4-downregula-
tion, MHC I-downregulation or infectivity enhancement. In some
cases, both CD42 and MHC I-downregulation were lost due to
effects on the association of Nef with cellular membranes, such as
the G2A mutation and probably also the adjacent substitutions at
positions 5–6. In other cases, these activities were lost due to a
decrease in Nef expression or stability. While this was most evident
for the changes at positions 178–179 and 180–181, some of the
substitutions in the globular core domain also had partial effects on
steady-state levels of Nef that may account for their reduced
activity in CD4 and MHC class I downregulation assays. Although
there was substantial overlap with sequences required for CD4-
downregulation, five mutations were identified that disrupted the
anti-tetherin activity of Nef, while retaining nearly wild-type levels
of CD4-downregulation, as well as MHC class I-downregulation
and infectivity enhancement. These mutations included alanine
substitutions at positions 106–107 in the core domain and at
positions 181–182, 193–194, 199–200 and 209–210 in the flexible
loop region. Thus, tetherin antagonism by Nef is genetically
separable from other functional activities of the protein.
In addition to the sequences identified by Zhang et al. [37], we
identified residues in the flexible loop region outside of the known
AP-2 binding sites that separate tetherin antagonism from CD4-
downregulation. Substitutions at positions 181–182 and 199–200
(residues N181V182 and Q199T200 in SIVmac239 Nef) specifically
impaired the anti-tetherin activity of Nef without affecting CD4-
downregulation. These residues are well conserved among Nef
alleles of SIVsmm/mac and HIV-2 isolates, with identities of 61.1%
for N181, 75% for V182, 94.4% for Q199 and 84.7% for T200 (Los
Alamos database; http://www.hiv.lanl.gov/content/index). Co-
immunoprecipitation assays further demonstrated that these
residues contribute to AP-2 binding. Our mutational analysis
also identified residues in the N-terminal and globular core
domains of Nef that are important for tetherin antagonism. Thus,
our results reveal that the anti-tetherin activity of Nef is
dependent on complex interactions involving multiple residues
in the N-terminus, globular core and the flexible loop regions of
the protein.
Nef is a multifunctional accessory protein that interacts with a
number of different cellular factors to modulate cellular trafficking
[55]. Nef reroutes MHC I molecules from the trans-Golgi network to
lysosomes via AP-1 and promotes the internalization and lysosomal
degradation of CD4 via AP-2 [55,59,60,61]. Nef also enhances virus
infectivity by an undefined mechanism that depends on a physical
interaction with Dyn2 [40]. We previously demonstrated that Nef
downmodulates tetherin from the surface of SIV-infected and
transfected cells [15,36], and this activity was later shown to occur
by an AP-2-dependent pathway [37]. Our experiments with
dominant-negative mutants of AP180 and Dyn2 confirm that the
internalization of tetherin by Nef, and the capacity of Nef to rescue
virus release in the presence of tetherin, depends, at least in part, on
clathrin-mediated endocytosis. A role for Dyn2 was further
demonstrated by showing that Dynasore, a chemical inhibitor of
dynamin, suppressed wild-type SIV replication to an extent
comparable to nef-deleted SIV under conditions of interferon-induced
upregulation of tetherin. Since Dyn2 is also required for Nef-
mediated infectivity enhancement, the inhibition of virus replication
by Dynasore may reflect an additional effect of this compound on
virus infectivity. Although tetherin antagonism and infectivity
enhancement are genetically separable, 10 of the 12 Nef mutants
that lost the ability to enhance virus infectivity, and to bind to Dyn2,
also lost the ability to counteract tetherin. The concordance of these
activities suggests that a physical interaction with Dyn2 may be
necessary for both Nef functions. However, two of the mutations in
the globular core disrupted infectivity enhancement and binding to
Dyn2 without impairing tetherin antagonism. Moreover, three of the
mutants with impaired infectivity enhancement and binding to Dyn2
(mutants 82–83, 146–147 and 168–169) did not lose binding to
tetherin, suggesting that Nef uses distinct protein surfaces to bind to
Dyn2 and to tetherin. Therefore, unlike infectivity enhancement, the
anti-tetherin activity of Nef does not depend on a physical interaction
with Dyn2.
Consistent with previous studies demonstrating the downmodula-
tion of rhesus tetherin by Nef [15,36,37], SIV infection resulted in a
striking redistribution of tetherin from the plasma membrane to
compartments within the cell. An analysis of the distribution of tetherin
in SIV-infected cells revealed co-localization with TGN46 and LAMP-
1, but not with CD63, suggesting that in the presence of Nef, tetherin
accumulates in the trans-Golgi network and in lysosomes. Localization
of tetherin to the trans-Golgi network in uninfected cells has previously
been reported [48]. Thus, the contribution of Nef to directing tetherin
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to that compartment is unclear. The trafficking of tetherin to lysosomes
raises the possibility that, similar to the effect of HIV-1 Nef on CD4
and MHC class I molecules [49], SIV Nef may direct rhesus tetherin
for lysosomal degradation.
In summary, we show that the mechanism of tetherin
antagonism by SIV Nef; (1) involves a direct physical interaction
between the core domain of Nef and the cytoplasmic domain of
rhesus tetherin, (2) requires sequences throughout the N-terminal,
globular core and flexible loop domains, yet is genetically
separable from other functional activities of Nef, and (3) depends,
at least in part, on clathrin-mediated endocytosis. These results
begin to reveal the molecular interactions and cellular pathways by
which the majority of the primate lentiviruses counteract the
tetherin proteins of their non-human primate hosts.
Materials and Methods
Plasmid DNA constructs
(a) BST 2 expression constructs. Human BST-2 (hBST-2)
and rhesus macaque BST-2 allele rBST-2.1 were cloned as
previously described [15,36].
(b) SIV proviral clones. Full-length proviral DNA clones for
wild-type SIV, SIV Denv and SIV Dnef were constructed from the
following clones based on SIVmac239; p239SpSp5’, pSP72-239-3’
and pSP72-239-3’Dnef [62,63].
(c) Nef expression constructs. SIV Nef was cloned into the
expression vector pCGCG-239-Nef as previously described
[15,36]. Mutations in Nef were introduced by Quickchange site-
directed mutagenesis according to the manufacturer guidelines
(Stratagene, La Jolla, CA).
(d) Dominant-negative mutants. The dominant negative
mutant AP180C and Dyn1K44A were kindly provided by Dr.
Min Dong (New England Primate Research Center, South-
borough, MA). AP180C was flag-tagged and cloned into pCMV,
whereas Dyn1K44A was HA-tagged and cloned into pCDNA.
The dominant-negative mutant Dyn2K44A, as well as wild-type
Dyn2, was kindly provided by Dr. John Guatelli. These constructs
were cloned into pEGFP N1.
Virus release assays
293T cells were co-transfected with wild-type or nef-deleted SIV
proviral DNA (100 ng) and pcDNA3-tetherin or pcDNA3-tetherin
mutants (50 ng). Differences in the amount of plasmid DNA in
each transfection were offset by the addition of empty pcDNA3
vector (50 ng). Either pCGCG, pCGCG-Nef or pCGCG-Nef
mutants (100 ng each) were provided in trans to assess the ability of
the Nef mutants to rescue virus release. All transfections were
performed in duplicate in 24-well plates seeded the day before at
56104 cells per well, using GenJet Lipid Transfection Reagents
(SignaGen Laboratories, Gaithersburg, MD). Forty-eight hours
post-transfection, the amount of virus released into the cell culture
supernatant was measured by SIV p27 antigen-capture ELISA
(Advanced Bioscience Laboratories, Inc., Kensington, MD), and
virus release was expressed as the percentage of maximal particle
release in the absence of tetherin, as previously described [15,36].
Western blots
Forty-eight hours post-transfection, 293T cell lysates were
prepared by harvesting in 26 SDS sample buffer. Virions were
recovered from the cell culture supernatant by centrifugation at
13,000 rpm for 2 hours at 4uC, and resuspended in 26 SDS
sample buffer. Samples were boiled for 5 minutes, and separated
by electrophoresis on 12% SDS-polyacrylamide gels and trans-
ferred to polyvinylidine fluoride (PVDF) membranes using a
Trans-Blot SD transfer cell (BioRad, Hercules, CA). The
membranes were then blocked with 5% non-fat dry-milk in PBS
containing 0.05% Tween-20 for 1 hour, and probed overnight at
4uC with one of the following primary antibodies. Tetherin/BST-
2 was detected with a mouse polyclonal antibody (abcam cat
#ab88523, Cambridge, MA) at a dilution of 1:500. The SIV Gag
proteins p27 and p55 were detected with the mouse monoclonal
antibody 183-H12-5C (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) at a dilution of 1:1000.
SIV Nef was detected using the mouse monoclonal antibody 17.2
(AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH) at a dilution of 1:1000. Endogenous b-actin
was detected with the monoclonal antibody C4 (Chemicon,
Billerica, MA) at a dilution of 1:1000. HA-tagged Dyn1K44A was
detected with the HA-specific mouse monoclonal antibody HA.11
(Covance, Princeton, NJ) at a dilution of 1:1000. The GFP fusion
proteins Dyn2 and Dyn2K44A were detected using an anti-GFP
mouse monoclonal antibody (Sigma-Aldrich, St Louis, MO) at a
dilution of 1:1000. The dominant-negative mutant AP180C was
detected with a mouse monoclonal FLAG-specific antibody
(Sigma-Aldrich, St Louis, MO) at a dilution of 1:1000. After
rinsing the PVDF membranes three times for 10 minutes in PBS
0.05% Tween-20, the blots were probed with an HRP-conjugated
goat anti-mouse secondary antibody (Pierce, Rockford, IL) at a
dilution of 1:2000 for 1 hour at room temperature. The blots were
then rinsed three more times in PBS 0.05% Tween-20, treated
with SuperSignal West Femto Maximum Sensitivity substrate
(Pierce, Rockford, IL), and imaged using a Fujifilm Image Reader
LAS 3000 (Fujifilm Photo Film Co., Japan).
Co-immunoprecipitation assays
293T cells (66105 cells) were co-transfected with constructs
expressing wild-type and mutant forms Nef (2 mg) along with
rhesus tetherin, human tetherin, tetherin mutants, Dyn2-GFP or
empty vector (pCDNA3) (2 mg). Twenty-four hours later, cells
were lysed with 400 ml of Lysis buffer (Thermo Scientific,
Rockford, IL) and incubated on ice for 30 minutes. Lysates were
transferred to a 1.5 ml tube and insoluble cell debris was removed
by centrifugation at 3,000 rpm. Cell lysate (200 ml) was set aside to
confirm tetherin and Nef expression by western blot analysis, and
the rest of the sample (200 ml) was used for immunoprecipitation.
Samples for immunoprecipitation were incubated on a rotating
platform for 1 hour at 4uC with 1 mg of the anti-tetherin mouse
monoclonal antibody 3H4 (Sigma-Aldrich, St Louis, MO). Protein
A sepharose beads or Protein A sepharose magnetic beads (50 ml)
(GE Healthcare, Piscataway, NJ) were then added, and the
incubation was continued overnight at 4uC. The beads were
washed ten times in Lysis buffer (500 ml) and boiled in 26 SDS
sample buffer. Denatured proteins were separated on 12% SDS-
polyacrylamide gels and transferred to PVDF membranes. The
blots were probed with the monoclonal antibody 17.2 to detect
Nef, a mouse monoclonal to detect GFP (Sigma-Aldrich, St Louis,
MO), a monoclonal antibody to detect the a2 subunit of AP-2
(Sigma-Aldrich, St Louis, MO), a rabbit monoclonal to detect the
m2 subunit of AP-2 (abcam, Cambridge, MA) at a dilution of
1:1000, or a polyclonal antibody against tetherin (abcam, Cam-
bridge, MA) at a dilution of 1:500. Membranes were next probed
with an HRP-conjugated goat anti-mouse antibody (Pierce,
Rockford, IL), a goat anti-mouse heavy chain specific antibody
(abcam, Cambridge, MA), or goat anti-rabbit secondary antibody
(abcam, Cambridge, MA), developed in SuperSignal West Femto
Maximum Sensitivity substrate and imaged using a Fujifilm Image
Reader LAS 3000 as described above. Quantification of the
association between Nef and rhesus tetherin, Nef and AP-2 or Nef
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and Dyn2 was performed by determining the band density from
western blots using ImageJ software (Rasband, W.S., Image, US.
NIH, Bethesda, MD, http://rsb.info.nih.gov/ij, 1997–2008).
Tetherin cytosolic domain peptides
Synthetic peptides (21st Century Biochemicals) corresponding to
the cytoplasmic domain of rhesus macaque (MAPILY-
DYRKMPMDDIWKEDGDKRCK) and human (MASTSY-
DYSRVPMEDGDKRCK) tetherin were biotinylated via stable
thioester bonds at conserved cysteine residues (underlined in
sequences shown above). In human tetherin cysteine at position 9
was replaced by serine (italics) in order to avoid multiple labeling.
Additional tetherin peptides (rA14-A18, hDDIWK and rD10) were
generated to further define the binding interface with Nef. These
peptides were also biotinylated at the conserved cysteine residues
mentioned above. Biotinylation was carried out for 2 hours at
room temperature and pH 6.5 to 7.0 with a 10-fold molar excess
of maleimide-PEG2-Biotin (Pierce), followed by reverse-phase
HPLC purification using a C18 Vydac 4.66250 mm analytical
column (Vydac, Hesperia, CA) with linear acetonitrile gradient (0–
72%) in 0.1% TFA (1 mL/min). Fractions containing the
biotinylated peptides were identified by mass-spectrometry, pooled
and lyophilized.
Recombinant Nef protein expression and purification
A nearly full-length SIVmac239 Nef protein (residues 4–263),
the core domain (residues 96–237) and different Nef deletion
mutants lacking residues in the flexible loop were expressed in
E. coli BL21 (DE3) as 6-His-thioredoxin fusion proteins and
purified as described previously by Sigalov et al. [54]. After cell
lysis with phosphate/Tris buffered 8 M urea solution (pH 8), the
fusion protein was purified by affinity chromatography using
NiNTA (Qiagen) under denaturing conditions (8 M urea), and
refolded by dialysis against 20 mM Tris pH 8.0, 150 mM NaCl,
0.1 mM DTT. The soluble fusion protein was digested with
thrombin (MP Biochmicals) leaving both the full-length protein
and the core domain of SIVmac239 with two additional N-
terminal residues (GS). Further purification was performed by
anion-exchange chromatography (POROS 20 HQ, Applied
Biosystems) and size-exclusion chromatography (Superdex 200,
GE Healthcare).
Surface plasmon resonance
Surface plasmon resonance experiments were carried out on a
BIAcore 3000 instrument at 25uC. Neutravidin (approximately
30,000 resonance units (RU)) were coupled to a CM5 sensor chip
(GE Healthcare) in 10 mM acetate buffer pH 5.0, and 0.005% (v/
v) surfactant P20 at 10 ml/min using standard amine coupling
protocols. Excess activated dextran carboxylate groups were
capped with ethanolamine. Biotinylated peptides of tetherin
(rBST-21–26 and hBST-21–21) were captured (3,000 RU) in
different neutravidin-coupled experimental flow cells leaving one
flow cell unmodified as a neutravidin-only control surface. Nef
binding was studied at 25uC in PBS under reducing conditions
(5 mM DTT). Purified samples of full-length, core domain or
flexible loop deletion mutants of SIVmac239 Nef protein were
injected at a flow rate of 5 ml/min over each experimental and
control flow cell generating SPR sensorgrams. The sensorgram
from the control cell was subtracted from the sensorgram of each
experimental flow cell to correct for any nonspecific interaction
with the CM5 or neutravidin surface. No regeneration step was
required. Experiments were run in triplicate. For equilibrium
analysis RU binding levels at equilibrium were extrapolated from
each sensorgram (corrected for nonspecific interaction) in the
concentration series, and plotted against concentration to derive a
binding curve that was fit to a hyperbolic equation y = RUmax*x/
(Kd.app+x), where y is the observed RU value, x is the
concentration of Nef, and adjustable parameter RUmax and Kd.app
are the RU value at saturation and the apparent binding constant
(Kd.app), respectively.
MHC class I and CD4 downregulation in transfected
Jurkat cells
Ten million Jurkat cells were electroporated with bicistronic
pCGCG constructs (40 mg) that express wild-type Nef, or Nef
mutants, and green fluorescent protein (GFP) from a downstream
internal ribosomal entry site. Twenty-four hours later, cells were
stained with a PerCP-conjugated monoclonal antibody to CD4
(BD Pharmingen, Billerica, MA) and an APC-conjugated mono-
clonal antibody to MHC-I (HLA-ABC, Dako, Carpinterı´a, CA).
After gating on the GFP+ cells, the mean fluorescence intensity
(MFI) of CD4 and MHC I expression was determined. Data was
collected using a FACSCalibur flow cytometer (Becton Dickenson)
and analyzed using FlowJo 8.8.7 software (TreesStar).
Infectivity enhancement assays
293T cells were co-transfected with nef-deleted SIV proviral
DNA (100 ng) and either pCGCG, pCGCG-Nef or pCGCG-Nef
mutants (100 ng each). All transfections were performed in
duplicate in 24-well plates seeded the day before at 56104 cells
per well, using GenJet Lipid Transfection Reagents (SignaGen
Laboratories, Gaithersburg, MD). Forty-eight hours post-transfec-
tion, the amount of virus released into the cell culture supernatant
was measured by SIV p27 antigen-capture ELISA (Advanced
Bioscience Laboratories, Inc., Kensington, MD). Next, 50 ng of
p27 equivalents for each virus were inoculated overnight onto
GHOST X4/R5 cells seeded the day before in 12-well plates at
2.56104 cells per well. Twenty-four hours later, cells were washed
and kept in fresh media. Forty-eight hours post-infection, cells
were fixed and analyzed by flow cytometry as described above.
The amount of infected cells was determined by calculating the
percentage of GFP+ cells, and the infectivity of each Nef mutant
relative to wild-type Nef was determined.
Tetherin downregulation assays
293T cells stably expressing HA-tagged rhesus tetherin (56104
cells) were transfected with 200 ng of pCGCG-Nef (or Nef
mutants) or empty vector. In the case of experiments with
dominant-negative mutants of endocytic pathways, cells were also
transfected with 300 ng of each of the expression vectors coding
for the dominant-negative mutants or empty vectors. Twenty-four
hours post-transfection, cells were briefly trypsinized and stained
for the surface expression levels of tetherin with a primary mouse
monoclonal anti-HA antibody (Covance, Princeton, NJ) at a
dilution of 1:4 and a secondary donkey anti-mouse APC-
conjugated antibody (BD Pharmingen, Billerica, MA) at a dilution
of 1:40. Cells were gated on the GFP+ population and the levels of
tetherin at the cell surface were determined by calculating the
MFI. The percentage of tetherin present at the plasma membrane
was calculated by dividing the MFI obtained in each transfection
by the MFI obtained in transfections with empty vectors. Data was
collected using a FACSCalibur flow cytometer (Becton Dickenson)
and analyzed using FlowJo 8.8.7 software (TreesStar).
Virus replication curves with Dynasore
Two million 221 T cells, a Herpesvirus saimiri-immortalized
rhesus macaque CD4+ T cell line [47], were infected in duplicate
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with 20 ng p27 of SIVmac239 and SIVmac239 Dnef. After 3 h of
incubation at 37uC, cells were washed three times and resus-
pended in 5 ml of R20+IL-2 (100 U). One day post-infection cells
were treated with 100 U of IFNa, and 8 hours later one of the
replicates was treated with 20 mM of Dynasore. Virus replication
was monitored at selected time points by p27 antigen-capture
ELISA of the culture supernatant.
Confocal microscopy
293T cells stably expressing HA-tagged rhesus macaque
tetherin (26104 cells in a 8-well slide) were infected with VSV-G
pseudotyped SIVmac239 Denv (50 ng p27 eq.). Twenty-four hours
later, cells were washed and fixed for 10 minutes in acetone/
methanol and blocked for 20–60 minutes with 100 mM glycine
diluted in 10% normal goat serum in PBS with 0.2% fish skin
gelatin, 0.1% Triton6100 and 0.02% sodium azide (10% NGS-
PBS-FSG-Tx100-NaN3). The cells were then washed three times
in 10% NGS-PBS-FSG-Tx100-NaN3, and stained. The mouse
monoclonal antibodies 17.2 (IgG1) and 3H4 (IgG2a) were used at a
dilution of 1:250 to stain for Nef and tetherin, respectively. The
cells were subsequently stained with Alexa-488- and Alexa-568-
conjugated goat anti-mouse secondary antibodies specific for IgG1
and IgG2a, respectively (Invitrogen, Grand Island, NY) (1:1000),
and with TO-PRO3 (Invitrogen) (1:5000) to visualize cell nuclei.
To stain intracellular compartments, rabbit polyclonal antibodies
specific for TGN46 (Sigma-Aldrich, St Louis, MO), CD63 (Santa
Cruz Biotechnology, Santa Cruz, CA) and LAMP-1 (abcam,
Cambridge, MA) were used at a dilution of 1:50. Next, an Alexa-
568 goat anti-rabbit (Invitrogen, Grand Island, NY) was used to
detect these cellular markers. In this case, Nef staining was
performed by using a secondary Alexa-633-conjugated goat anti-
mouse IgG1. After staining, the cells were washed and mounted on
slides with antiquenching mounting-medium (Vector Laborato-
ries, Inc). Images were acquired using a Leica TCS SP5 II
confocal microscope.
Supporting Information
Figure S1 Comparison of protein expression in cell
lysates to the accumulation of SIV p27 in the cell culture
supernatant. Western blots were performed to compare protein
levels in cell lysates and virions resulting from transfections with
Nef mutants with impaired anti-tetherin activity. Membranes were
developed with antibodies specific for tetherin, p55 Gag, p27 CA,
Nef, tetherin and b-actin.
(TIF)
Figure S2 Analysis of Nef proteins with deletions in the
flexible loop region for binding to rhesus tetherin and
TCRf. Representative SPR traces for the binding of Nef96–237 (A)
and Nef96–237 D197–205 (B) to a peptide corresponding to the
cytoplasmic domain of rhesus tetherin. Representative SPR traces
for the binding of Nef96–237 (C) and Nef96–237 D197–205 (D) to a
peptide corresponding to residues 65–80 of the TCRf chain
cytoplasmic domain. (E) Estimated Kd values for the binding of
recombinant SIV Nef96–237 proteins with the indicated deletions in
the flexible loop region to a peptide corresponding to residues 65–
80 of the TCRf chain peptide.
(TIF)
Figure S3 Analysis of tetherin peptides for direct
binding to Nef. Representative SPR traces for the binding of
Nef96–237 and rhesus tetherin (A), a tetherin mutant lacking 10
amino acids (B), a rhesus tetherin mutant containing alanine
substitutions at positions 14–18, (C) and a human tetherin mutant
containing residues D14DIWK18 from rhesus tetherin (D).
(TIF)
Figure S4 CD4-downregulation by SIV Nef mutants with
impaired anti-tetherin activity. (A–D) Jurkat cells were
electroporated with bicistronic constructs expressing each of the
SIV Nef mutants and GFP. Cells were stained with a PerCP-
conjugated monoclonal antibody to CD4 and the MFI of CD4
staining, indicated in the upper right corner of each plot, was
determined after gating on the GFP+ cell population.
(TIF)
Figure S5 MHC class I-downregulation by SIV Nef
mutants with impaired anti-tetherin activity. (A–D) Jurkat
cells were electroporated with bicistronic constructs expressing
each of the SIV Nef mutants and GFP. Cells were stained with an
APC-conjugated anti-HLA class I-specific monoclonal antibody
and the MFI of MHC class I staining, indicated in the bottom
right corner of each plot, was determined after gating on the GFP+
cell population.
(TIF)
Figure S6 Identification of residues in SIV Nef required
for infectivity enhancement. The infectivity of SIV Dnef trans-
complemented with Nef mutants containing alanine substitutions
at the indicated positions was determined using GHOST X4/R5
cells. Virus was produced by co-transfecting 293T cells with
SIVmac239 Dnef proviral DNA, a construct expressing wild-type or
mutant Nef, or empty vector (pCGCG). GHOST X4/R5 cells
were infected with 50 ng of p27 equivalents of each virus, and the
percentage of infected GFP+ cells was determined by flow
cytometry 48 hours after infection. The relative infectivity of
SIV Dnef trans-complemented with mutants in the N-terminal
domain (A), the globular core domain (B), and the flexible loop
region (C) is shown in comparison to SIV Dnef trans-complemented
with wild-type Nef (black) and without trans-complementation
(white). The black dotted lines indicate 5 standard deviation above
the infectivity observed for SIV Dnef without trans-complementa-
tion. (D) Nef mutants with impaired infectivity enhancement
(below 5 standard deviations of SIV Dnef activity) were tested for
binding to Dyn2 by co-immunoprecipitation. 293T cells were co-
transfected with expression constructs for the indictated Nef
mutants, and either Dyn2-GFP or an empty vector (V). Cell lysates
were immunoprecipitated with a monoclonal antibody to GFP and
western blots were probed with antibodies to Nef and GFP. The
ratios of the band intensities for Nef versus Dyn2 in the
immunoprecipitated samples are shown beneath each lane.
(TIF)
Figure S7 Subcellular distribution of tetherin in unin-
fected cells. 293T cells expressing HA-tagged rhesus tetherin
were stained for tetherin (HA) (green), Nef (red) and either
TGN46, CD63 or LAMP-1 (blue). The white scale bar indicates
25 mm.
(TIF)
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